Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
March 25, 2020NeuroRx is leading US development of RLF-100 (Aviptadil) on behalf of Relief Therapeutics' (RLF)
WILMINGTON, DE and RADNOR, PA March 25, 2020 / NeuroRx, a clinical stage biopharma company focused on development of CNS drugs, today announced an expansion of scope to include the co-development...
-
February 10, 2020
NeuroRx will update investors at the upcoming BIO CEO conference on Monday, February 10, 2020 at 10:15am. The company's CEO, Dr. Jonathan Javitt will be presenting an overview of recent results...
-
January 8, 2020Company to attend upcoming JP Morgan Healthcare Conference
NeuroRx, Inc announced that it has received a notice of patent allowance covering the Composition of Matter for its drug NRX-101, which targets suicidal bipolar depression, an unmet medical need...
-
November 12, 2019Conducting Phase 3 trial for NRX-101, an FDA-designated Breakthrough Therapy for Suicidal Bipolar Depression
WILMINGTON, DE - November 12, 2019 / NeuroRx, Inc. (NeuroRx) a clinical stage biopharma company focused on development of drugs targeting depression and suicidality, announced today that it will...
-
October 23, 2019
NeuroRx, Inc (NeuroRx) announced that it has signed an agreement with GEM Global Yield LLC SCS ("GEM"), the New York based private alternative investment group to provide the NeuroRx with up to...
-
September 9, 2019
NeuroRX, a phase 3 biopharma company focused on development of NRX-101, an FDA-designated Breakthrough Therapy for Severe Bipolar Depression with Acute Suicidal Ideation, will present a corporate...
-
July 9, 2019Pivotal study will test novel, oral antidepressant in maintaining remission from Severe Bipolar Depression with Acute Suicidal Ideation & Behavior following initial stabilization with ketamine
NeuroRx, Inc., a clinical stage biopharma company focused on development of drugs targeting depression and suicidality, announced today that it has initiated a pivotal Phase 2b/3 study for NRX-101...
-
June 3, 2019First drug targeting suicidal bipolar depression, awarded FDA Breakthrough Therapy Designation
NeuroRX, a clinical-stage biopharma company developing the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation or Behavior, will present phase 2 efficacy results from its...
-
May 30, 2019Findings suggest potential efficacy for NRX-101 in maintaining remission from Severe Bipolar Depression with Acute Suicidal Ideation following initial stabilization with ketamine.
NeuroRx, a clinical stage biopharma company focused on development of drugs to target suicidal depression and PTSD, announced statistically significant final results from its Phase 2 STABIL-B...
-
December 13, 2018Findings suggest potential for NRX-101 in maintaining remission from Severe Bipolar Depression with Acute Suicidal Ideation following initial stabilization with ketamine
WILMINGTON, Del. - NeuroRx, a clinical stage biopharma company focused on the development of Rapid Acting Antidepressants (RAADs) that target the brain’s NMDA receptor, announced results from...
-
November 13, 2018First oral Rapid-Acting Antidepressant to be granted Breakthrough Designation
WILMINGTON, Del. - NeuroRx, a clinical stage biopharma company focused on the development of Rapid Acting Antidepressants (RAADs) that target the brain’s NMDA receptor, has been granted...
-
September 5, 2018
WILMINGTON, Del., Sept. 05, 2018 -- NeuroRx, a clinical stage biopharma company developing NRX-101, the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior...
-
September 4, 2018
WILMINGTON, De. , Sept. 04, 2018 -- NeuroRx, a clinical stage biopharma company developing NRX-101, the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior...
-
June 11, 2018
WILMINGTON, Del. - NeuroRx, Inc., a clinical stage biopharma company has completed the feasibility enrollment phase of its 2b/3 clinical trial of NRX-101 for the treatment of suicidal bipolar...
-
May 7, 2018FDA deems proposed Phase 2b/3 trial adequate to support a regulatory submission
WILMINGTON, Del., May 07, 2018 -- NeuroRx, a clinical stage biopharmaceutical company developing the first drug regimen to treat Severe Bipolar Depression in patients with Acute Suicidal Ideation...
-
January 3, 2018Company to present at J.P. Morgan Healthcare Conference in San Francisco January 10th, 2018
NeuroRx, a clinical stage biopharma company developing the first drug regimen to treat Severe Bipolar Depression in patients with Acute Suicidal Ideation & Behavior (ASIB), announced that it has...
-
December 27, 2017Third clinical research site for NRX-100 / NRX-101 phase 2B/3 clinical study
NeuroRx, a clinical stage biopharma company developing the first drug regimen to treat severe bipolar depression in patients with Acute Suicidal Ideation and Behavior (ASIB), announced that it has...
-
September 6, 2017Company to present at Rodman and Renshaw Global Investment Conference in New York City on Sept 12, 2017
NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), has been granted Fast Track status by the US Food and Drug...
-
April 12, 2017Recent hospitalization is a risk factor for further suicide attempts -- potentially related to patient care perceptions
WILMINGTON, Del. - NeuroRx launches the first global “Voice of the Patient Survey” for those diagnosed with bipolar disorder, in collaboration with leading patient advocacy groups, mental...
-
March 24, 2017Company developing NRX-101 – first potential biomarker-based oral treatment for Acute Suicidal Ideation & Behavior in Bipolar Depression
Wilmington, Delaware , March 24, 2017 -- NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that...
-
March 19, 2017Company developing NRX-101 – first potential biomarker-based oral treatment for Acute Suicidal Ideation & Behavior in Bipolar Depression
Wilmington, Delaware , March 20, 2017 -- NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that...
-
February 10, 2017Company developing NRX-101 – first potential treatment for Acute Suicidal Ideation in Bipolar Depression
Wilmington, Delaware & Tel Aviv, Israel , Feb. 10, 2017 -- NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today...
-
January 4, 2017Clinical stage biopharma company advances development of first-in-class drug to decrease the risk of suicide in those suffering from bipolar depression
Biotech Showcase at the JP Morgan Healthcare Conference NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB) in Bipolar...
-
December 21, 2016
Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi, "Lethal Generosity: The Key to Your...
-
December 21, 2016
Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi, "Lethal Generosity: The Key to Your...
Click here to view our corporate presentation or on the image below